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Background: Multi-institutional, international practice variation of pediatric anaphylaxis 47 
management by healthcare providers has not been reported. 48 
Objective: Characterize variability in epinephrine administration for pediatric anaphylaxis 49 
across institutions, including frequency and types of medication errors. 50 
Methods: A prospective, observational, study using a standardized in situ simulated anaphylaxis 51 
scenario was performed across 28 healthcare institutions in six countries. The on-duty 52 
healthcare team was called for a child (patient simulator) in anaphylaxis. Real medications and 53 
supplies were obtained from their actual locations. Demographic data about team members, 54 
institutional protocols for anaphylaxis, timing of epinephrine delivery, medication errors, and 55 
systems safety issues discovered during the simulation were collected. 56 
Results: Thirty-seven in situ simulations were performed. Anaphylaxis guidelines existed in 41% 57 
(15/37) of institutions. Teams used a cognitive aid for medication dosing 41% (15/37) of the 58 
time and 32% (12/37) for preparation. Epinephrine auto injectors (EAIs) were not available in 59 
54% (20/37) of institutions and were used in  only 14% (5/37) simulations. Median time to 60 
epinephrine administration was 95 seconds (IQR 77, 252) for EAI and 263 seconds (IQR 146, 61 
407.5) for manually prepared epinephrine (p=.12). At least one medication error occurred in 62 
68% (25/37) of simulations. Prior nursing experience with epinephrine administration for 63 
anaphylaxis was associated with fewer preparation (p=.04) and administration (p=.01) errors. 64 
Latent safety threats (LSTs) were reported by 30% (11/37) of institutions, more than half of 65 
these (6/11) involved a cognitive aid. 66 
Conclusion and Relevance: A multicenter, international study of simulated pediatric 67 
anaphylaxis reveals: 1) variation in management between institutions in usage of protocols, 68 
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cognitive aids, and medication formularies, 2) frequent errors involving epinephrine, 3) LSTs 69 
related to cognitive aids among multiple sites.  70 
Highlights box: (35 words)  71 
What is already known about this topic? Factors impacting patient safety in pediatric 72 
anaphylaxis management across healthcare institutions are unknown.  73 
What does this article add to our knowledge? Preventable medication errors involving 74 
epinephrine are more prevalent than previously recognized.  75 
How does this study impact current management guidelines? Variability for use of protocols, 76 
cognitive aids, and medication formularies exist. 77 
Keywords: simulation, anaphylaxis, medication error, autoinjector, epinephrine 78 
Abbreviations: EAI (Epinephrine auto injector), EI (Epinephrine injection), IM (Intramuscular), IV 79 
(Intravenous), ED (Emergency department), ICU (Intensive care unit), LST (Latent safety threat), 80 
PI (Principal investigator), IQR (Interquartile range), WAO (World Allergy Organization) 81 
  82 
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Anaphylaxis is a severe, life threatening, systemic allergic reaction that is rapidly 84 
progressive and potentially fatal.(1) In the United States, estimated lifetime prevalence is at 85 
least 1.6% with an increasing incidence globally and in children. (2) Rapid deterioration and 86 
death can occur within minutes from the onset of symptoms, and prompt reversal can occur 87 
after administration of intramuscular (IM) epinephrine.(3-4) Delays in epinephrine treatment 88 
increase the risk of adverse outcomes including mortality.(5,6) The recommended dose and 89 
route for treating pediatric anaphylaxis is 0.01 mg/kg administered IM in the vastus lateralis 90 
muscle.(1) IM epinephrine is given via an epinephrine injection (EI) or an epinephrine auto-91 
injector (EAI). EI requires that the epinephrine dose be calculated and drawn up from a vial into 92 
a syringe whereas EAIs deliver a single dose of epinephrine via a disposable, pre-filled, 93 
automatic injection device.   94 
A review of the literature from 1990-2015 by Cohen et al. found an extensive list of 95 
hazards involving epinephrine use for anaphylaxis.(7) However, only a small number of single- 96 
center, observational and descriptive studies have reported on errors by healthcare providers 97 
associated with EI compared to EAI delivery.(8, 9) Knowledge and skill gaps in the use of the EAI 98 
among healthcare providers have been identified. (8,10) There is no published multi-center 99 
overview of clinical or simulation research comparing the prevalence of errors with EI versus 100 
EAI in the management of anaphylaxis by healthcare providers.(8) 101 
Randomized controlled trials of anaphylaxis management are currently not feasible 102 
given the life-threatening nature of this condition. Additionally, anaphylaxis has an 103 
unpredictable incidence with varied presentations across different clinical disciplines 104 
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throughout healthcare systems. Standardized in situ simulation-based assessments have been 105 
used to investigate quality of care across a spectrum of healthcare systems without the 106 
unpredictability, variability and higher stakes inherent to studying care delivered to actual 107 
patients.(11,12) In situ simulation research involves bringing the simulator into the clinical 108 
environment to assess the quality of care delivered by intact care teams using real-world 109 
equipment.(13) Potential safety concerns, or latent safety threats (LSTs), are often exposed. We 110 
utilized simulation-based assessments to examine management of anaphylaxis in pediatric 111 
patients across different healthcare institutions. 112 
Our primary objective was to characterize variability in practices across institutions 113 
related to epinephrine administration, the frequency and types of epinephrine medication 114 
errors, and to explore factors associated with errors. We hypothesized that errors would be 115 
more likely to occur with EI than with EAI and sought to investigate the point prevalence of 116 
errors in anaphylaxis management in children during in situ simulation.  117 
  118 
Downloaded for Anonymous User (n/a) at Indiana University Ruth Lilly Medical Library from ClinicalKey.com by Elsevier on December 02, 2019.





Study Design 120 
This was a prospective, multicenter, international simulation-based study of the 121 
management of pediatric anaphylaxis at various patient care locations in healthcare 122 
institutions. We report our study in accordance with reporting guidelines for simulation-based 123 
research extensions for the STROBE statement.(14) Recruitment of a convenience sample 124 
began March 2018 via email and social media (Twitter) advertisement directed to members of 125 
the International Network for Simulation-based Pediatric Innovation, Research and Education 126 
(INSPIRE), the Pediatrics section of the Society for Simulation in Healthcare (SSH) and the 127 
International Pediatric Simulation Society (IPSS). Healthcare institutions that care for pediatric 128 
patients capable of performing a single in situ anaphylaxis simulation scenario within a six-129 
month period were included. Multiple simulations from a single institution were allowed if they 130 
were performed on different clinical units with unique healthcare teams. Each site principal 131 
investigator (PI) obtained local institutional review board approval for exempt status. 132 
Institutions unable to obtain approval and accomplish the simulation within the specified time 133 
were excluded. As these simulations were performed in the real work environment, feasibility 134 
depended on competing clinical demands, thus, a six-month period allowed flexibility in 135 
scheduling the simulation.  136 
Setting 137 
 Twenty-eight institutions from six countries (Israel, Spain, Lebanon, Germany, New 138 
Zealand, and 16 states in the United States) submitted data from 37 simulated events that 139 
occurred May 4 through November 20, 2018.  Almost all simulations (n=36) were performed in 140 
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tertiary or quaternary care academic children’s hospitals, ranging in size from 30 to over 300 141 
pediatric beds, and 81% (n=30) cared soley for pediatric patients. Only one simulation was 142 
performed in the emergency department (ED) of a community hospital. Three institutions (11%) 143 
performed the scenario in more than one clinical location. Simulations took place most often in 144 
the ED (38%), followed by the inpatient non-oncology floor (30%) and the intensive care unit 145 
(ICU) (16%). Other locations included an infusion center, procedural sedation unit and oncology 146 
clinic (see Table I). 147 
Simulation Scenario 148 
The scenario, created by a multidisciplinary group of simulation experts, involved a five 149 
year-old, 20 kilogram (kg) child with a history of peanut and drug allergies who has an 150 
anaphylactic reaction after receiving an intravenous (IV) medication. The human patient 151 
simulator manikin had an IV catheter in place at the start of the simulation and demonstrated 152 
clinical symptoms of anaphylaxis as allowed by the individual simulator. The scenario ended 153 
after epinephrine was administered. The procedures for selection of the in situ environment 154 
and delivery of the simulation (including pre-simulation script and post-simulation debriefing) 155 
were standardized (see eMethods in the Online Repository). The following components of the 156 
simulation were site specific and not standardized: brand of simulator, IV medication causing 157 
the allergic reaction, use of video recording, pre-announcement of the simulation to 158 
participants, team composition, and team leader.  159 
Site PIs were directed to choose an in situ environment that would allow the on duty 160 
healthcare team to respond. The scenario started with calling the team for help with a patient 161 
in anaphylaxis, thus obviating the need to recognize and diagnose an allergic drug reaction. 162 
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Participants managed the anaphylaxis scenario as they would in real life. Real medications and 163 
supplies for the administration of epinephrine were obtained from their authentic locations in 164 
the clinical space. Immediately after the simulation, the team participated in a post-165 
performance debriefing focused on adherence to anaphylaxis guidelines, drug dosing and 166 
administration errors, as well as the identification of systems, patient or staff safety concerns.  167 
Data collection 168 
Demographic data were obtained to characterize the simulation team and understand 169 
the local standards for anaphylaxis and epinephrine administration. Data collected using a 170 
standardized form included: site demographics (availability of EAI and in which locations, 171 
existence of local anaphylaxis guidelines), dose, concentration, route, correct site of 172 
administration and the timing of epinephrine delivery. This data was provided by the site PI. 173 
Time dependent metrics were verified after reviewing video recordings when available. Data 174 
was entered into a central server, associated with the SSH International Simulation Data 175 
Registry, over a web-based, password protected collection tool.  176 
Published anaphylaxis guidelines for dosing were used to define correct dose, and for a 177 
20 kg child this is the 0.15 milligram (mg) autoinjector or 0.01 mg/kg, i.e. 0.2 mg.(1) The correct 178 
concentration is 1:1000 or 1 mg/milliliter (ml) for EI. The correct route is IM. It was also 179 
considered a separate error if specifics on dose, concentration or route were not prescribed 180 
(i.e. the practitioner only said “Let’s give epi.”). The site PI was instructed to position 181 
themselves so they could observe the medication preparation process to ensure correct volume 182 
and concentration was drawn up. An administration error for EAI use was recorded if the device 183 
was not held in place for 3 seconds. (15)  Medication errors in prescribing (dose, concentration, 184 
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route), preparation (dose and concentration) or administration (route or location), as well as 185 
safety issues discovered during the simulation were collected. An error in prescribing that was 186 
prepared and given as incorrectly prescribed could potentially be counted as 3 separate errors 187 
(one for prescribing, one for preparation and one for administration). This was because there 188 
was opportunity for the error to be caught and corrected at each of those time points.  189 
Statistical Analysis 190 
Data were summarized using frequency and percentage for categorical variables and 191 
medians with interquartile range (IQR) for continuous. Demographic and simulation team 192 
factors associated with medication errors were evaluated using odds ratio (OR) and 95% 193 
confidence intervals (CI) were assessed using univariate logistic regression with Firth’s 194 
penalized likelihood for small sample size. Differences in time to order and time to 195 
administration of epinephrine were assessed using Wilcoxon rank sum tests. Primary analysis 196 
includes all simulation events from each site. Within-site correlation was not accounted for due 197 
to limitations of sample size. Sensitivity analysis using one simulation event per site was 198 
performed and results were substantively similar (not shown). All analyses were conducted 199 
using SAS 9.4 (SAS Institute, Cary, NC) with two-sided p-values <0.05 considered statistically 200 
significant. 201 
  202 
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Table I lists simulation site and team characteristics. Teams included at least one nurse and 204 
practitioner (physician or advanced practice nurse/physician assistant) for all simulations. An 205 
EAI was used in five (14%) simulations. Only 46% (17/37) of simulations reported having an EAI 206 
available somewhere in their institution, not necessarily throughout all locations. The sites in 207 
Israel, Lebanon and New Zealand do not have any epinephrine autoinjectors available in their 208 
hospitals. The sites in Spain used Jext® and the United States and Germany used EpiPen®. 209 
Institutions using EAI as first-line therapy in some, but not all, areas of the hospital stocked 210 
them mostly within medication dispensing units (47%) and in radiology (41%). Table E1 in the 211 
online repository has specifics about which locations EAI are available as first line therapy and 212 
how they are stored.  213 
Epinephrine errors 214 
At least one error was made in 68% (25/37) of simulations. Of the five events using EAI: 215 
40% (n=2) of errors were due to over-dosing, 20% (n=1) included an error in administration (i.e. 216 
injection duration less than 3 seconds per recommendations).(15) Of the 32 events utilizing EI: 217 
53% (n=17) involved an error only in prescribing, 16% (n=5) had an error only in preparation 218 
and 9% (n=3) had separate errors made during both prescribing and preparation. Figure 1 219 
shows the progression and propagation of EI and EAI errors. In two events, the medication 220 
dose, concentration, and route (i.e., all 3 parameters) were not specified. Epinephrine was 221 
ordered to be administered IV in 24% (n=9). A specific intramuscular location for giving 222 
epinephrine was not specified in 43% (16/37), although we did not count this as an error.  223 
Figure 2 is a Pareto chart showing types of errors in descending order of frequency. There were 224 
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five “near miss” events involving a prescribing error that was caught and did not reach the 225 
patient.  226 
System-level safety hazards 227 
Nearly one-third of sites (n=11) discovered one or more safety hazards during 228 
simulations. More than half of these (n=6, 54%) involved problems with usability or design of a 229 
cognitive aid, such as missing anaphylaxis dosing, dosing only listed in milligrams and not 230 
milliliters, cardiac arrest dosing used, and conflicting dosing recommendations. Table E2 in the 231 
Online Repository contains additional details related to latent safety threats. 232 
Risk factors for errors 233 
Estimated odds ratios for presence of at least one medication error by site and team 234 
characteristics are shown in Table II. Teams that had a nurse with prior experience giving 235 
epinephrine for anaphylaxis were significantly associated with events without medication 236 
preparation errors (OR = 0.2, 95% CI = [0.04, 0.93], p = .04) and with events without 237 
administration errors (OR = 0.13, 95% CI = [0.03, 0.62], p = .01). There were an insufficient 238 
number of sites using EAI to compare error rates with EI in a meaningful way.  239 
Table III compares times from medication ordering to administration for EI to EAI use. 240 
Although the difference was not statistically significant, the median time to administration 241 
between the two forms of epinephrine was over 2.5 minutes longer for EI. Time to prepare the 242 
EAI dose was significantly shorter (p=.02) than for EI.  243 
  244 
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Discussion:  245 
This is the first, multi-center prospective, observational study to investigate the 246 
variability and vulnerabilities of pediatric anaphylaxis management in healthcare institutions, 247 
many of which are academic, pediatric medical centers. The primary objective was to 248 
characterize variability in practices across institutions related to epinephrine administration, 249 
the frequency and types of epinephrine medication errors, and to explore factors associated 250 
with errors.  The key results of this study are that, in this cohort, errors in anaphylaxis 251 
management are common in clinical sites specialized in pediatric acute or critical care. High 252 
rates of both prescribing errors and IV administration were observed during the management 253 
of a simulated child with anaphylaxis. The use of an EAI and the presence of an anaphylaxis 254 
guideline have the potential to improve safety but both were uncommon in this cohort and not 255 
associated with reduced error. (7,16) Prior nursing experience giving epinephrine for 256 
anaphylaxis was the only protective factor against preparation and administration errors.  257 
At least one medication error was made in 68% of events. Medication dosing in 258 
pediatrics is weight-based and more complex than for adults, thus most pediatric medication 259 
errors occur during the prescribing stage and are related to dosing errors (17,18). In this study, 260 
the most common errors centered on incorrect prescribing of epinephrine, which occurred with 261 
both EAI and EI, followed by errors in EI preparation. Prescribing errors that were not caught 262 
resulted in the administration of epinephrine via the IV route in 24% of cases that used EI. The 263 
errors noted in this cohort pose a significant potential for harm due to the narrow therapeutic 264 
index and systemic cardiovascular side effects of epinephrine.(19) Variations in indications for 265 
epinephrine use, concentration, routes of administration, commercial delivery devices and 266 
Downloaded for Anonymous User (n/a) at Indiana University Ruth Lilly Medical Library from ClinicalKey.com by Elsevier on December 02, 2019.




nomenclature to express dosages and concentrations all contribute to potential for error. (20-267 
22)  268 
Standardization of the administration of epinephrine through the use of EAI or storing 269 
pre-filled syringes of epinephrine specifically designated for IM use in anaphylaxis have the 270 
potential to reduce errors.(7,21) Only two sites reported EAI as first line therapy throughout 271 
their institution whereas an additional 15 sites have EAI available in select locations. Only 29% 272 
(5/17) of teams with access to an EAI chose to use one to respond to a simulated case of 273 
anaphylaxis. Fifty-four percent of sites do not have EAI available at their institution at all. The 274 
small number of institutions using EAI precluded identification of a statistically significant 275 
difference in error rates compared with EI. We observed that EAI use was associated with an 276 
almost 3-minute reduction in the median time to administer epinephrine compared to the 277 
median time of 4.4 minutes to administration of EI. This delay in treatment is concerning as 278 
anaphylaxis can lead to death in less than five minutes. (3)  Increased costs, drug shortages and 279 
device recalls can be barriers to the standardization of EAI use for anaphylaxis within healthcare 280 
systems.(23) As these barriers may not change quickly, it is important to have a mechanism to 281 
examine prevalence of epinephrine errors across institutions, understand their causes, and 282 
share successful risk mitigation plans in order to prevent patient harm.  283 
Fewer than half the sites identified having an anaphylaxis protocol. The World Allergy 284 
Organization (WAO) guidelines recommend having a written protocol for management of 285 
anaphylaxis.(16) A clinical guideline is of particular use for anaphylaxis, an event that is low 286 
frequency per practitioner, and may cause confusion to practitioners about appropriate 287 
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 The presence of an identified guideline was not significantly associated with 288 
decreased frequency of errors in this study.  289 
There was low overall use of cognitive aids in this study with only 41% of simulation 290 
teams utilizing aids for prescribing and 32% for preparing medication doses. Cognitive aids, 291 
which may include checklists, flowcharts, and posters, can improve the speed and accuracy of 292 
task completion, including improving outcomes and decreasing the number of errors in 293 
emergency situations.(26)  There was no significant association between cognitive aid use and 294 
decreased frequency of error in our study.  295 
Cognitive aids are widely underused as they require good design, easy access, and a 296 
supportive systemic environment.(27) More than half of the latent safety threats reported in 297 
this study involved errors found in institutional cognitive aids themselves. Hazards included 298 
missing anaphylaxis dosing on the aids, dosages listed in milligrams but not milliliters (thus 299 
requiring hand-calculation of the volume), practitioners selecting cardiac arrest instead of 300 
anaphylaxis dosages, conflicting dosage recommendations, and an outdated cognitive aid with 301 
the incorrect suggested route (subcutaneous) of administration. In these instances, the design 302 
of the cognitive aid itself created a vulnerability for errors. 303 
Prior nursing experience administering epinephrine for anaphylaxis was significantly 304 
associated with simulations that were free of medication preparation and administration 305 
errors. In emergent situations, nurses are the ones who typically prepare and administer 306 
medications and thus play a key role in catching and preventing prescribing errors. (28) 307 
Previously reported knowledge and experience gaps of the prescribing practitioner as well as 308 
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the medication nurse may be important contributors to error during management of 309 
anaphylaxis and key targets for intervention.(29,30) 310 
We have several recommendations to improve anaphylaxis management and patient 311 
safety based on our findings. Systems-based interventions could include establishment, 312 
dissemination and education of a written guideline or protocol for anaphylaxis management as 313 
recommended by the WAO. Additionally, institutions should regularly review their cognitive 314 
aids to ensure  accessibility, clarity and accuracy. Less than one third of institutions with EAI 315 
available used them during these simulations. Use of an EAI, or having an experienced nurse on 316 
site might result in decreased error rates and more timely preparation and appropriate 317 
administration of epinephrine for anaphylaxis. Additional training using interprofessional 318 
anaphylaxis simulations could focus on 1) awareness of the high risk of medication errors, 2) 319 
familiarization with cognitive aids 3) use of aids for preparation and administration of 320 
epinephrine and 4) exploration of barriers to EAI use in institutions with EAI available. 321 
This study has several limitations. Limitations intrinsic to simulation-based studies 322 
include the fact that simulated scenarios may not fully mimic real life, which may impact the 323 
speed and efficiency of health care providers’ actions. To mitigate this, we used an in situ 324 
simulation and instructed sites to approximate an authentic response as much as possible, 325 
including use of real medications and equipment. Simulation studies run the risk of potential 326 
unmeasured confounders including deviations in conducting the scenario, differences in team 327 
composition, and practice variation over time. We attempted to mitigate these by using a very 328 
simple, standardized scenario and limiting the time period for its performance. Generalizability 329 
may be limited as this study was performed mostly in academic pediatric institutions with 330 
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simulation programs in North America and may not be as relevant in institutions with different 331 
attributes.  332 
These preliminary results should be confirmed with a larger sample. Our study was 333 
underpowered to detect statistically significant differences in errors between EAI and EI. 334 
However, it provides preliminary pilot data on the proportion of EAI use at institutions and the 335 
error rate with EI to understand what sample size is needed for an appropriately powered 336 
study.  337 
Conclusion 338 
This multicenter, international, prospective observational study of simulated pediatric 339 
anaphylaxis confirms wide variability among healthcare institutions for usage of protocols, 340 
cognitive aids, and medication formularies, timing of epinephrine dose delivery, and types of 341 
medication errors made. Prior nursing experience with giving epinephrine for anaphylaxis was 342 
significantly associated with fewer preparation and administration errors. There was an 343 
unexpectedly low rate of EAI use, and not all teams with access to EAIs used them.  344 
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Figure 1: Pathways for error propagation during 32 simulation events using manually drawn up 460 
epinephrine (1a) and five events with epinephrine autoinjectors (1b). Simulation-discoverable 461 
medication errors and opportunities for correction differ between these formulations. Rx = 462 
prescribed, Med Prep= medication preparation, Admin = administration, Pt = patient, Tx = 463 
treatment 464 
 465 
Figure 2: Pareto chart with decreasing frequency of epinephrine errors from 37 simulations. 466 
Some had more than one error. Prescribing of concentration and route and preparation errors 467 
are not applicable for epinephrine autoinjectors. Admin = administration, conc = concentration, 468 






  475 
Downloaded for Anonymous User (n/a) at Indiana University Ruth Lilly Medical Library from ClinicalKey.com by Elsevier on December 02, 2019.






Table I: Simulation and Site Characteristics (n=37) 
 
  N % 
Institution Specialty     
Pediatric 30 81 
Mixed (adult and pediatric) 7 19 
Anaphylaxis protocol/guideline    
No/Unsure 22 59 
Yes 15 41 
Institution allows use of patient’s EAI
a 
   
No/Unsure 21 57 
Yes 16 43 
EAI
a
 available somewhere in institution    
No/Unsure 20 54 
Yes 17 46 
EAI
a
 as first line therapy throughout institution (n=17)    
No 15 88 
Yes 2 12 
EAI
a
 as first line therapy in some areas of hospital (n=15)    
No/Unsure 4 27 
Yes 11 73 
Simulation Location   




Inpatient floor (Non-Oncology) 11 30 
Other  6 16 
Team composition:     
Resident 27 73 
Fellow 9 24 
Attending 11 30 
Advance Practice Nurse/Physician Assistant 6 16 
Pharmacist 3 8 
Experience of team leader    
5 or more years of clinical experience (after residency) 7 19 
Less than 5 years of clinical experience (after residency) 9 24 
trainee (resident) 21 57 
Nursing experience    
Never given epinephrine for anaphylaxis 12 32 
Given EI
c
 for anaphylaxis at least once 17 46 
Given EAI
a
 for anaphylaxis at least once 8 22 
Cognitive aid used for prescribing 15 41 
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  476 Cognitive aid used for preparation 12 32 
a
EAI = Epinephrine auto injector, 
b
ICU = Intensive care unit 
c
EI = Epinephrine injection 
Downloaded for Anonymous User (n/a) at Indiana University Ruth Lilly Medical Library from ClinicalKey.com by Elsevier on December 02, 2019.




Table II: Odds ratio estimates for risk factors associated with epinephrine error 477 






OR 95% CI 
p-
value 
OR 95% CI 
p-
value 
Nursing with prior epinephrine 
administration for anaphylaxis 
0.65 (0.15,2.78) 0.56 0.2 (0.04,0.93) 0.04 0.13 (0.03,0.62) .01 
Other Location vs. Intensive 
Care Unit 
3.18 (0.46,22.22) .24 5.13 (0.58,45.45) .14 1.02 (0.15,7.09) .99 
Other Location vs. Emergency 
Department 
1.77 (0.42,7.46) .44 2.42 (0.57,10.31) .23 1.32 (0.29,5.99) .72 
Inexperienced team lead
c 
2.01 (0.50,8.13) .33 2.93 (0.66,13.11) .16 2.84 (0.55,14.71) .21 
Less than 3 anaphylaxis 
simulations/year 
1.8 (0.47,6.90) .39 1.11 (0.29,4.26 .88 2.25 (050,10.10) .29 
No attending on team 2.62 (0.61,11.24) .19 1.44 (0.34,6.10) .63 2.42 (0.46,12.66) .30 
No pharmacist on team 2.1 (0.18,23.91) .55 1.32 (0.12,15.09) .82 3.89 (0.12,127.78) .44 
Institution has EAI
d 
3.89 (0.33,45.61) .28 1.4 (0.12,16.43) .79 0.41 (0.04,4.33) .46 
EAI used 0.61 (0.17,2.22) .46 0.36 (0.09,1.41) .14 0.79 (0.20,3.15) .74 
Cognitive aid used for dosing 1.73 (0.44,6.81) .44 0.91 (0.24,3.51) .89 0.87 (0.21,3.77) .87 
Cognitive aid used for 
preparation 
0.94 (0.23.3.90) .93 1.07 (0.28,4.44) .92 0.21 (0.03,1.50) .12 
Protocol/Guideline 2.27 (0.59,8.82) .24 1.93 (0.51,7.34) .33 1.74 (0.43,6.95) .43 
Pediatric (vs mixed) institution 1.67 (0.32,8.75) .55 0.53 (0.10,2.77) .45 1.13 (0.19,6.61) .89 
 
a
OR = odds ratio, 
b
CI = confidence interval. 
c
Inexperienced team lead = still in residency 478 
training, EAI
d 
= epinephrine auto injector
 479 
  480 
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Table III: Comparison of time (in seconds) by form of epinephrine used during simulation 




 Auto injector (n=5)     
p-value  Time from Median  IQR
b 
Median  IQR 
Start to order
c 
91.5 (37.5, 227.5) 49 (38, 184) .74 
Order to administration 114 (62, 174.5) 28 (26, 68) .02 
Start to administration
d 






IQR= interquartile range, Start time = when the team engages in the 482 
scenario, just after they are told the patient is in anaphylaxis from an intravenous medication. 483 
c
Start to order = the time to when the practitioner finishes verbally ordering the epinephrine 484 
medication. 
d
Start to administration = the time to when the epinephrine was administered, 485 
includes medication preparation 486 
 487 
 488 
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Reasons for Epinephrine Error
Occurrences Cumulative Percents
14.1% 12.9% 12.9% 10.6% 3.5%29.4% 16.5%
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eMethods: Simulation scenario instructions 
 
Choosing which clinical site to perform your simulation 
We ask that the scenario be performed “in situ”, and not in a simulation center, because 
we are interested in recreating and capturing what happens in real life. You can choose 
which clinical environment to perform the scenario- the ED, ICU, radiology, inpatient 
floor, etc. I would base your choice on which location will be most receptive to you 
coming to run a simulation that meets these requirements: 
1) We would like to use a healthcare team that is “on duty” and most representative of 
the team that would normally respond and manage a patient in anaphylaxis on that 
unit. This will depend on your location. For my hospital, typically a resident, nurse 
practitioner or fellow and a nurse would manage such a patient. Perhaps an attending 
would also be involved. I would not want a team of just medical students because that is 
not a realistic representation for my institution.  
There may be some sites that are less accustomed to running a simulation in the real 
clinical environment. If this is the case, you may want to recruit a healthcare team to 
participate or provide a prebrief so that the team knows to behave as they would in real 
life. There will be a question on the data collection survey that asks if this simulation 
was partially announced or unannounced.  
2) We would like to use real medications. So, the staff participating in the simulation 
should go to where epinephrine is stored on the unit and obtain it from there for med 
preparation. On some units, this may be an epi auto-injector that is kept in the 
medication room. Other units may open the crash cart to obtain the epinephrine and 
manually draw up the drug from a vial. We know that epi auto-injectors are quite 
expensive, so if you would like to substitute either an expired one or a trainer, that is ok. 
Just switch it out at the last minute.  
Preparing for data collection during the simulation 
Please review the data collection form and demographics form so you will know what to 
look for as you observe the simulation.  
1) Timed metrics that we are interested in:  
• Time 0 = when the healthcare team starts the simulation (typically when the 
nurse or practitioner goes to assess the patient) after they have been given the 
starting prompt by the simulation team. 
• Time elapsed for the epinephrine to be ordered, even if the dose is not specified.   
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o This time is for when the verbal order is given (not when it is entered into 
a computer).  
o Some practitioners may just ask for “a dose of epi for anaphylaxis” but 
not give the dose until later when asked. Please record the earlier time 
but make a note that the dose was not specified. This will be a question 
in the online data collection tool. 
• Time elapsed before the epinephrine is administered in relation to the start of 
the simulation.  
It would be best if you can video record the simulation to ensure accuracy of these 
times. It does not have to be super high tech. I am planning on just using my iPhone to 
record this. For some of you, it may be that you use a stopwatch as your timer.  After 
you have collected the timed metrics, you can delete the video. I do not need it for this 
study. 
2) Try to position yourself close to the medication preparation area so that you can 
watch for any mistakes that are made. Did they choose the right dose and concentration 
of epi? Did they use the correct route of administration? If an auto-injector is used, did 
they know how to use the auto-injector correctly? The drug should be administered IM 
in the anterolateral thigh. For the auto-injectors, they should be held in place for at least 
3 secs if not longer. (Please know that some healthcare staff have accidentally injected 
themselves when using auto-injectors. If you see that is about to happen, it would be ok 
to stop them.) 
The simulation scenario 
We purposely chose a very simple scenario because we wanted to make sure we could 
standardize it across sites. No confederate or parent needs to be involved or trained. 
We are not testing to see if participants can diagnose anaphylaxis. We want to see what 
they do to treat anaphylaxis. 
Equipment/Set Up 
1. 5 year old manikin (high of low fidelity) with a PIV in place.  
 
2. Cardiorespiratory monitor for manikin.  
Starting vitals: HR 155, CR flash, BP 88/30, RR 26, saturations 94%, wheezing and 
increased WOB, normal mental status 
Weight - 20 kg 
3. Epinephrine supplies that your institution would normally have available such as an 
Epi Auto-injector, code cart, drug tray, syringes and needles for IV, subcutaneous, 
and intramuscular dosing, etc. Try to use the equipment that is already present in 
the real clinical setting.  
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4. Institutional reference or medication dosing cognitive aid, as particular to each site. 
 
5. Smart phone or video recording device to capture timed metrics.  
 
Script to tell participants: 
“Please come evaluate this patient. He just received an IV antibiotic and is now covered 
in hives and is having trouble breathing. He has a history of anaphylaxis and he is in 
anaphylaxis now.  He weighs 20 kg.” 
 
Remember to start video recording, or start your stop watch once you finish telling the 
simulation participants this and they being the simulation = Time 0. 
 
Scenario End: Right after the epinephrine is administered, the vitals can return to a 
normal state.  
 
Debriefing 
You can use whatever debriefing style you prefer. Any obvious errors (ex. medication 
error) should be debriefed.  
 
Let the team know what the objectives of the scenario were and give them the option of 
not participating in the study. This was the statement included in the IRB application: 
 
“The anaphylaxis scenario you just participated is an attempt to gain a better 
understanding of how pediatric anaphylaxis is managed both in our institution and at 
others. Information regarding epinephrine dosing, preparation and administration was 
collected. Any video recording performed was to ensure accuracy of timed metrics and 
drug preparation. The video will be destroyed immediately after this data is obtained. 
Results will be analyzed as research data.  No identifying information will be included in 
any report, abstract, or publication originating from this data.  This study is voluntary, 
and you may choose to not participate at any time by simply notifying the simulation 
team.” 
Examples of questions you could use if relevant to their performance: 
1. Tell me more about the strategies you used that helped you to administer the 
correct dose of epinephrine for anaphylaxis so quickly. 
 
2. Is there anything you would do differently the next time this happens? 
 
3. Did anything surprise you about this scenario? Were there any non-routine 
events? How were those managed?  
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4. Epinephrine is a high-risk medication and there have been errors made by 
multiple healthcare providers because of confusion over the correct 
concentration/ dosing/ route of administration. For example, the 1:1000 
concentration for anaphylaxis has been given via the IV route. This has resulted 
in significant patient side effects including arrhythmias and hypertension.  
a. What do you think could have gone wrong in that case?  
b. Have any of you had a similar experience with epinephrine before? 
Perhaps a near-miss where the error was caught before it reached the 
patient? 
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Table E1: Characteristics of sites (n=17) with epinephrine auto injectors (EAI) 
  N % 
Locations where EAI is first line therapy (% of sites with EAI available) 
Emergency Department 5 29 
Oncology inpatient unit 5 29 
Inpatient unit (Non-Oncology) 2 12 
Intensive Care Unit 0 0 
Operating Room 0 0 
Radiology 7 41 
Outpatient clinic 3 18 
High reaction areas 2 12 
Where EAIs are stored  (% of sites with EAI available) 
Code cart 1 6 
Medication dispensing unit 8 47 
Code Go bag 1 6 
Unit-specific medication box 7 41 
 
 
 Table E2: Specific Latent Safety Threats 
General Process 
• No Standard Operating Procedure is available for Epinephrine use in 
our ED’s anaphylaxis response. 
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• There are delays in administering Epi because nursing is unable to 
draw up medications for a patient until the patient is registered in 
our 2 computer systems. 
• Outdated anaphylaxis protocol exists involving use of Epi Pen, but 
autoinjectors are no longer available at the hospital. 
Specific Process: 
Cognitive Aid 
• There is no anaphylaxis dosing of epinephrine on the code sheet. 
• Dosing on anaphylaxis sheet is written in mg (not mL), which caused 
a delay in administration because nursing needed to calculate the 
volume to be administered. 
• Nursing staff was not familiar with the dosing book available at 
every crash cart. The nurse almost drew up the arrest dose of 
epinephrine but at the last minute saw the heading entitled 
"anaphylaxis." 
• Inappropriate labelling of Epi for anaphylaxis on the code sheet. 
• Our pre-made code sheets do not have an anaphylaxis dose, so our 
team saw the 1:1000 Epinephrine dose listed for ETT administration 
and used this inappropriate dosing. 
• IM dosing of epinephrine not on code sheets. 
• Outdated cognitive aid recommending subcutaneous route. 
• Two cognitive aids present in same room but with different doses 
listed for anaphylaxis. 
• The fellow used a PALS card which lists both IM and IV dosing (IV 
use for hypotension) and he inappropriately chose IV. 
Knowledge Gap 
• Dosing for anaphylaxis was unknown.  The wrong volume and 
concentration were asked for making the order a correct 'dose' but 
incorrect concentration and route of epinephrine administration. 
• There was inadequate knowledge of our hospital process for 
anaphylaxis. 
• Due to a recent shortage of epinephrine, the nursing staff has been 
diluting 1:1,000 epinephrine to the 1:10,000 concentration for 
cardiac arrest. So they inadvertently diluted the anaphylaxis dose as 
well. 
• Staff not aware that Epi Pens were stocked in our PYXIS 
Specific Process 
Pyxis 
• Epi Pen and Epi Pen Jr. should be stocked in the PYXIS for all units. 
However, not all units had Epi Pen Jr stocked and when stocked it 
was not available for override in case of emergency. 
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• There was a several minute delay in administration of Epinephrine 
because the team did not know how to obtain the anaphylaxis kit 




• Medical team was unable to find the Epi pen in timely manner. 
• Anaphylaxis kit had epinephrine ampule without filter needle, 
causing a significant delay in care. 
• The two different concentrations of epi are in bags with warning 
stickers. However, the bags look exactly the same which caused the 
wrong concentration to be utilized. 
• Pediatric code cart (in a community ED) was not appropriately 
stocked. Supplies had been previously removed for other patients 
and not replaced. 
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